Clinical Trials in Tennessee

Showing 6901-6920 of 20,239 trials

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

NCT05953688

This is a multi-center, randomized, double-masked, proof-of-concept study in patients with Active Noninfectious Intermediate, Posterior, or Panuveitis.

Uveitis Posterior Non-InfectiousUveitis, IntermediateNoninfectious Panuveitis

Alumis Inc36 participantsStarted Jun 2023

Beverly Hills, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +14 more locations

TERMINATEDPhase 229 miles

Guadecitabine Extension Study

NCT03603964

This is a multicenter, open-label extension study for participants who participated in a previous Astex-sponsored guadecitabine clinical study \[including but not limited to SGI-110-01 (NCT01261312), SGI-110-04 (NCT02348489), SGI-110-06 (NCT02920008), and SGI-110-07 (NCT02907359)\].

Acute Myeloid LeukemiaMyeloid Dysplastic Syndrome

Astex Pharmaceuticals, Inc.35 participantsStarted Jul 2018

Buffalo, New York, United States • Durham, North Carolina, United States • Columbus, Ohio, United States +18 more locations

POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU

Guadecitabine Extension Study

Find Trials by Condition in Tennessee

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Drug Reduction in Older Patients: The DROP Trial

Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)

Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence

SGI-110 in Combination With Carboplatin in Ovarian Cancer

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Open Label, 6-month Study for High Frequency and Chronic Migraine,